<DOC>
	<DOCNO>NCT02693158</DOCNO>
	<brief_summary>The primary objective multicenter , single-arm , observational study evaluate feasibility systematic direct stenting strategy Svelte SLENDER IDS Sirolimus-Eluting Coronary Stent-on-a-Wire Integrated Delivery System ( SLENDER IDS ) all-comers , real-world population .</brief_summary>
	<brief_title>The Direct III Post Market Study</brief_title>
	<detailed_description>In post-market study , population include real-world subject intend treat , SLENDER IDS standard therapy . Follow-up contact post procedure make clinical assessment hospital discharge , 1 , 6 12 month . This study design prospective , multi-center , single-arm , observational all-comers clinical study collect ongoing safety efficacy SLENDER IDS determine feasibility direct stenting strategy all-comers population . A minimum two hundred fifty ( 250 ) subject treat 20 site Europe . Review safety data risk subject monitor independent Clinical Events Committee ( CEC ) pre-specified enrollment milestone .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1 . Subject â‰¥ 18 year old ; 2 . Subject symptomatic heart disease due coronary artery lesion length &lt; 28 mm reference vessel diameter 2.5 4.0 mm . 3 . Subject intend treated PCI implantation SLENDER IDS part his/her standard treatment 4 . Subject subject 's legal representative understands study requirement treatment procedure provide write informed consent study specific test procedure perform . 1 . Subject unable receive antiplatelet and/or anticoagulant therapy ; 2 . Subject allergic sirolimus , PEA III Ac Bz , cobalt , chromium , nickel tungsten ; 3 . The subject judge lesion prevent complete inflation angioplasty balloon proper placement coronary stent , include chronic total occlusion . 4 . Subject woman pregnant nursing ( pregnancy test must perform within 7 day prior index procedure woman childbearing potential , base standard care cath lab ) ; 5 . Subject participate another investigational drug device clinical trial investigator feel would interfere subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>